What a heartbreaking turn of events for a veteran pitcher whose career has been defined by resilience—yet again, Liam Hendriks faces a setback that could redefine his path in baseball. Dive into the latest chapter of this inspiring yet challenging journey, where the Boston Red Sox have made a tough call on his contract, and we'll explore what it means for both the team and the athlete.
But here's where it gets controversial... The Red Sox have officially decided not to exercise their side of a $12 million mutual option for right-handed relief pitcher Liam Hendriks, according to a report from Chris Cotillo of MassLive on X (formerly Twitter). This means Hendriks, the former elite closer, will collect a $2 million buyout and step back into free agency, giving him the freedom to pursue new opportunities elsewhere.
For those new to baseball contracts, a mutual option is like a built-in choice in the deal where both the team and the player can agree to extend the partnership for another season. In this case, it was worth $12 million, but the Red Sox opted out, leaving Hendriks with that smaller payout instead. This move doesn't shock many observers, given Hendriks' struggles over the past few years. To put it in simple terms, health issues have kept him sidelined, turning what could have been a triumphant return into a prolonged waiting game.
Let's rewind a bit to understand the full picture. Back in 2023, Hendriks battled non-Hodgkin's lymphoma, a type of cancer that affects the lymphatic system—it's serious and requires aggressive treatment, but he fought it off valiantly and was declared cancer-free. Unfortunately, just as he was gearing up to pitch again, he needed Tommy John surgery, a procedure that reconstructs the ulnar collateral ligament in the elbow to fix throwing injuries. He managed only five innings before that setback, showing how fragile his arm had become.
Heading into 2024, Hendriks entered free agency and landed a two-year contract with the Red Sox, guaranteed at $10 million. This contract structure included a $2 million salary for the first year, $6 million for the second, and then that $12 million mutual option with the $2 million buyout. The team knew going in that he might not pitch much in year one due to recovery, but they were betting on a strong comeback in year two, hoping he'd reclaim his spot as a top-tier closer—think of those high-pressure ninth-inning saves that can make or break a game.
And this is the part most people miss... It just didn't pan out. Hendriks sat out the entire 2024 season, and elbow issues persisted into 2025. He spent most of the year on the injured list, logging a mere 13 and 2/3 innings pitched. In September, he underwent ulnar nerve transposition surgery, a more targeted procedure to address nerve impingement in the elbow, which has left his recovery timeline uncertain. For beginners, imagine how frustrating it must be to have your passion—pitching in big-league games—put on hold by recurring elbow problems, especially after overcoming cancer.
Looking ahead, Hendriks will likely focus on rebuilding his health and strength in the coming months. He'll turn 37 in February, an age where many pitchers still have gas in the tank, but his future deals will hinge on how his elbow responds. He could be a prime candidate for another 'bounceback' contract, similar to how other veterans like Bartolo Colón or even recent examples like Tyler Glasnow have returned after injuries. But the question lingers: Is this a smart investment for any team, or a risky gamble?
Speaking of which, here's a point that might stir some debate—some fans argue the Red Sox should have held onto the option, believing in Hendriks' proven track record as a dominant closer before his health woes. After all, with proper rehab, he could return to form and provide much-needed relief in a competitive AL East. On the flip side, critics say the team did the right thing by cutting ties early, avoiding tying up payroll on an uncertain asset when they need reliable contributors now. What if this decision frees up resources for younger prospects or trades? It's a classic case of weighing loyalty to a veteran against pragmatic roster management.
Ultimately, Hendriks' story is one of perseverance amid adversity, reminding us that baseball careers can be unpredictable. As he navigates free agency, we'll be watching to see where he lands next. Do you think the Red Sox made a prudent choice, or were they too quick to let go of a player with Hendriks' grit? Should teams prioritize past performances over current health risks in contracts like this? Share your opinions in the comments below—we'd love to hear differing views and spark a conversation!
Photo courtesy of Ken Blaze, Imagn Images
View Comments (4)
